Jim Cramer Makes Big Claim About Beckton Dickinson (BDX)

We recently published Jim Cramer Revealed His Big AI Investing Fear & Discussed These 20 Stocks. Becton, Dickinson and Company (NYSE:BDX) is one of the stocks discussed by Jim Cramer.

Becton, Dickinson and Company (NYSE:BDX) is one of the largest medical devices and laboratory equipment providers in America. Its shares are up by 6.9% over the past year and are down by 3.8% year-to-date. Piper Sandler discussed Becton, Dickinson and Company (NYSE:BDX)’s shares on April 17th as it reduced the share price target to $159 from $170 and kept a Neutral rating on the stock as it adjusted its estimates to account for the firm’s latest guidance. On the 14th, RBC Capital had reduced the share price target to $175 from $195 and maintained a Sector Perform rating. The bank remarked that Becton, Dickinson and Company (NYSE:BDX) was not at the risk of demand disruption, as evidenced by intra-quarter checks. Cramer has discussed healthcare stocks quite a bit recently, and in this appearance, he insisted sticking with Becton, Dickinson and Company (NYSE:BDX) despite the lackluster share price performance:

“I had Tom Polen, the CEO of Beckton Dickinson. And that stock is at an historical low. A low, healthcare, you can’t give these stocks away.”

Source: Unsplash

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.